Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia?

No abstract is available for this paper.

• Publication year

  1984

• Venue

  Blood

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood.v63.4.921.921PMID 6200161
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Natural history of sickle cell anemia in Saudi Arabs. A study of 270 subjects.

  2020cited by this paper
• 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia.

  1983cited by this paper
• 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia.

  1982cited by this paper
• 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons.

  1982cited by this paper
• The Influence of Fetal Hemoglobin on the Risk of Complications of Sickle Cell Anemia

  1981cited by this paper
• F-cell production in sickle cell anemia: regulation by genes linked to beta-hemoglobin locus.

  1981cited by this paper
• Fetal hemoglobin and clinical severity of homozygous sickle cell disease in early childhood.

  1981cited by this paper
• The intracellular polymerization of sickle hemoglobin and its relevance to sickle cell disease.

  1981cited by this paper
• Lack of influence of fetal hemoglobin levels or erythrocyte indices on the severity of sickle cell anemia.

  1980cited by this paper
• Effect of other hemoglobins on gelation of sickle cell hemoglobin.

  1980cited by this paper
• The physical chemistry of the gelation of sickle hemoglobin.

  1980cited by this paper
• Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S.

  1979cited by this paper
• Comparison of sickle cell-beta0 thalassaemia with homozygous sickle cell disease.

  1979cited by this paper
• Sickle cell anemia and trait in Southern India: Further studies

  1979cited by this paper
• Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (first of three parts).

  1978cited by this paper
• Microchromatography of hemoglobins. VIII. A general qualitative and quantitative method in plastic drinking straws and the quantitative analysis of Hb-F.

  1978cited by this paper
• Fetal Haemoglobin Production and the Sickle Gene in the Oases of Eastern Saudi Arabia

  1978cited by this paper
• Individual variation in the production and survival of F cells in sickle-cell disease.

  1978cited by this paper
• Sickle β‐thalassemia: Identical twins differing in severity implicate nongenetic factors influencing course

  1976cited by this paper
• Quantitative microchromatographic determination of hemoglobin f in patients with hemoglobins s and/or c

  1976cited by this paper
• Linear Statistical Inference and Its Applications

  1966cited by this paper

• Global prevalence of elevated estimated pulmonary artery systolic pressure in clinically stable children and adults with sickle cell disease: A systematic review and meta-analysis

  2025cites this paper
• End Organ Affection in Sickle Cell Disease

  2024cites this paper
• Post-GWAS Validation of Target Genes Associated with HbF and HbA2 Levels

  2024cites this paper
• Vitamin D Deficiency and Avascular Necrosis in Patients With Sickle Cell Disease: A Retrospective Cohort Study

  2024cites this paper
• Temporal restriction of Cas9 expression improves CRISPR-mediated deletion efficacy and fidelity

  2024cites this paper
• Between hope and reality: treatment of genetic diseases through nucleic acid-based drugs

  2024cites this paper
• Genotyping the BCL11A Single Nucleotide Polymorphism and Associated Levels of Fetal Hemoglobin in Mauritanian Sickle Cell Patients.

  2024cites this paper
• Quantitative Model‐Based Assessment of Multiple Sickle Cell Disease Therapeutic Approaches Alone and in Combination

  2024cites this paper
• Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34+ cell therapy to induce fetal hemoglobin for sickle cell disease

  2024cites this paper
• Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies

  2023cites this paper
• Hydroxyurea treatment for adult sickle cell anemia patients in Kinshasa

  2023cites this paper
• Gene therapies for sickle cell disease: Effectiveness and value

  2023cites this paper
• Therapeutic adenine base editing of human hematopoietic stem cells

  2023cites this paper
• Effects of l‐arginine supplementation in patients with sickle cell disease: A systematic review and meta‐analysis of clinical trials

  2023cites this paper
• Novel lentiviral vectors for gene therapy of sickle cell disease combining gene addition and gene silencing strategies.

  2023cites this paper
• Gene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials

  2023cites this paper
• An Update on the Application of CRISPR Technology in Clinical Practice

  2023cites this paper
• Targeting Genetic Modifiers of HBG Gene Expression in Sickle Cell Disease: The miRNA Option

  2022cites this paper
• Phenotypic variation in sickle cell disease: the role of beta globin haplotype, alpha thalassemia, and fetal hemoglobin in HbSS

  2022cites this paper
• Gene editing for sickle cell disease and transfusion dependent thalassemias- A cure within reach.

  2022cites this paper
• MicroRNA29B induces fetal hemoglobin via inhibition of the HBG repressor protein MYB in vitro and in humanized sickle cell mice

  2022cites this paper
• Novel lentiviral vectors for gene therapy of sickle cell disease combining gene addition and gene silencing strategies

  2022cites this paper
• The Optimized γ-Globin Lentiviral Vector GGHI-mB-3D Leads to Nearly Therapeutic HbF Levels In Vitro in CD34+ Cells from Sickle Cell Disease Patients

  2022cites this paper
• Hydroxyurea and fetal hemoglobin effect on leg ulcers in patients with sickle cell disease

  2022cites this paper
• Examination of the primary fraction of hemoglobin in individuals having sickle cell disease using high-performance liquid chromatography

  2022cites this paper
• The association of the -158 XmnI γG globin polymorphism with HbF level in sickle cell anemia Sudanese Patients

  2022cites this paper
• Clinical and laboratory characterization of adult sickle cell anemia patients in Kinshasa

  2022cites this paper
• Evaluation of persistence and fate of ex vivo edited-HSC modified with donor template and Its role in correcting Sickle Cell Disease

  2021cites this paper
• CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease

  2021cites this paper
• Preclinical evaluation for engraftment of CD34+ cells gene-edited at the sickle cell disease locus in xenograft mouse and non-human primate models

  2021cites this paper
• The Role of Certain Congenital Infections in Aplastic Anemia and Prognostic Value of Fetal Hemoglobin as a Follow-Up Marker

  2021cites this paper
• A systems pharmacology model for gene therapy in sickle cell disease

  2021cites this paper
• Sickle cell disease: progress towards combination drug therapy

  2021cites this paper
• Delta‐globin gene expression improves sickle cell disease in a humanised mouse model

  2021cites this paper
• Prevalence of sickle cell disorders and malaria infection in children aged 1–12 years in the Volta Region, Ghana: a community-based study

  2020cites this paper
• CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.

  2020cites this paper
• Induction of therapeutic levels of HbF in genome‐edited primary β039‐thalassaemia haematopoietic stem and progenitor cells

  2020cites this paper
• Delta-Globin Gene Expression Is Enhanced in vivo by Interferon Type I

  2020cites this paper
• Sickle cell disease

  2020cites this paper
• Prevalence and risk factors for albuminuria and glomerular hyperfiltration in a large cohort of children with sickle cell anemia

  2020cites this paper
• Hemoglobin F mitigation of sickle cell complications decreases with aging

  2020cites this paper
• Individual red blood cell fetal hemoglobin quantification allows to determine protective thresholds in sickle cell disease

  2020cites this paper
• Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity

  2020cites this paper
• Hematopoietic stem cell gene therapy for the treatment of β-hemoglobinopathies

  2020cites this paper
• Genetic variants in the G gamma-globin promoter modulate fetal hemoglobin expression in the Colombian population

  2020influential citation
• Comparative analysis of lentiviral gene transfer approaches designed to promote fetal hemoglobin production for the treatment of β-hemoglobinopathies.

  2020cites this paper
• Potent and orally active purine-based fetal hemoglobin inducers for treating β-thalassemia and sickle cell disease.

  2020cites this paper
• Fetal hemoglobin rescues ineffective erythropoiesis in sickle cell disease

  2020cites this paper
• Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease.

  2020cites this paper
• Targeting sickle cell disease root-cause pathophysiology with small molecules

  2019cites this paper
• Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease

  2019cites this paper
• Association of fetal hemoglobin level with frequency of acute pain episodes in sickle cell disease (HbS-only phenotype) patients.

  2019cites this paper
• Evaluation of correlation between clinical profile and amount of abnormal hemoglobin in sickle cell hemoglobinopathy

  2019influential citation
• Can natural variation in erythroid microRNA‐29b be translated to sickle cell disease severity?

  2019cites this paper
• From fiction to science: clinical potentials and regulatory considerations of gene editing

  2019cites this paper
• Heritability of fetal hemoglobin, white cell count, and other clinical traits from a sickle cell disease family cohort

  2019cites this paper
• Genome editing of HBG1 and HBG2 to induce fetal hemoglobin.

  2019cites this paper
• Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements.

  2019cites this paper
• Gene Therapy for Beta-Hemoglobinopathies: Milestones, New Therapies and Challenges

  2019cites this paper
• RN-1, a Potent and Selective LSD1 Inhibitor, Increases γ-globin Expression, F-retics, and F-cells in a Sickle Cell Disease Mouse Model

  2019cites this paper
• Genetic Modifiers at the Crossroads of Personalised Medicine for Haemoglobinopathies

  2019cites this paper
• Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia

  2019cites this paper
• Wake-up Sleepy Gene: Reactivating Fetal Globin for β-Hemoglobinopathies.

  2018cites this paper
• A study on the genotype frequency of -158 Gγ (C→T) Xmn1 polymorphism in a sickle cell trait cohort from Siwa Oasis, Egypt.

  2018cites this paper
• Fetal hemoglobin gene expression in patients with sickle cell disease in North Central Nigeria

  2018cites this paper
• Compound Heterozygosity of β-Thalassemia and the Sickle Cell Hemoglobin in Various Populations of Chhattisgarh State, India

  2018cites this paper
• βS globin gene haplotype and the stroke risk among Egyptian children with sickle cell disease

  2018influential citation
• Fetal Hemoglobin Induction by Epigenetic Drugs.

  2018cites this paper
• Therapeutic applications of group I intron‐based trans‐splicing ribozymes

  2018cites this paper
• A microfluidic approach to study the effect of mechanical stress on erythrocytes in sickle cell disease.

  2018cites this paper
• Haemoglobin F and A2 profiles among sickle cell anaemia patients in Lagos State University Teaching Hospital (LASUTH), Nigeria

  2018cites this paper
• Sickle cell disease; An overview of the disease and its systemic effects.

  2018cites this paper
• A study on the genotype frequency of $$-158~\hbox {G}\gamma $$-158Gγ ($$\hbox {C}{\rightarrow }\hbox {T}$$C→T) Xmn1 polymorphism in a sickle cell trait cohort from Siwa Oasis, Egypt

  2018cites this paper
• Therapeutic strategies for sickle cell disease: towards a multi-agent approach

  2018cites this paper
• Low fetal hemoglobin percentage is associated with silent brain lesions in adults with homozygous sickle cell disease.

  2017cites this paper
• Variability of homozygous sickle cell disease: The role of alpha and beta globin chain variation and other factors.

  2017cites this paper
• Pulmonary hypertension among 5 to 18 year old children with sickle cell anaemia in Nigeria

  2017cites this paper
• A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy

  2017cites this paper
• Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study

  2017cites this paper
• Therapeutic strategies in Sickle Cell Anemia: The past present and future

  2017cites this paper
• Gene Therapy for β-Hemoglobinopathies.

  2017cites this paper
• Sickle Cell Disease

  2017cites this paper
• KLF1 drives the expression of fetal hemoglobin in British HPFH.

  2017cites this paper
• Emerging point-of-care technologies for sickle cell disease screening and monitoring

  2016cites this paper
• Avascular necrosis of the femoral head in sickle cell disease in pediatric patients suffering from hip dysfunction.

  2016cites this paper
• Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia.

  2016cites this paper
• Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the βA(T87Q)-Globin Gene

  2016cites this paper
• Minireview: Prognostic factors and the response to hydroxurea treatment in sickle cell disease

  2016cites this paper
• Treating hemoglobinopathies using gene-correction approaches: promises and challenges

  2016cites this paper
• Hydroxyurea in Sickle Cell Disease: Our Experience in Western India

  2016cites this paper
• Evolution of sickle cell disease from a life‐threatening disease of children to a chronic disease of adults: The last 40 years

  2016cites this paper
• Original Research: Use of hydroxyurea and phlebotomy in pediatric patients with hemoglobin SC disease

  2016cites this paper
• RN-1, a potent and selective lysine-specific demethylase 1 inhibitor, increases γ-globin expression, F reticulocytes, and F cells in a sickle cell disease mouse model.

  2015cites this paper
• Correlation between the Lactate Dehydrogenase Levels with Laboratory Variables in the Clinical Severity of Sickle Cell Anemia in Congolese Patients

  2015cites this paper
• Sickle Cell Disease: Reappraisal of the Role of Foetal Haemoglobin Levels in the Frequency of Vaso-Occlusive Crisis.

  2015cites this paper
• Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia

  2015cites this paper
• Progressive Glioblastoma Multiforme in a Patient with Sickle Cell Beta Thalassemia, Observations Following Combining Valproic Acid with Hydroxyurea

  2015cites this paper
• Potentially therapeutic levels of anti-sickling globin gene expression following lentivirus-mediated gene transfer in sickle cell disease bone marrow CD34+ cells.

  2015cites this paper
• Genetic variant in the BCL11A (rs1427407), but not HBS1-MYB (rs6934903) loci associate with fetal hemoglobin levels in Indian sickle cell disease patients.

  2015cites this paper
• Fetal Hemoglobin Levels in Patients With Sickle Cell Disorders and its Correlation With Disease Severity

  2015cites this paper